HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kurtulus Sahin Selected Research

N(4)-oleylcytosine arabinoside

10/2022Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry.
1/2018Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
8/2017Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
11/2015Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
8/2014Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kurtulus Sahin Research Topics

Disease

7Atrial Fibrillation
08/2017 - 08/2014
6Venous Thromboembolism
10/2022 - 08/2014
6Stroke (Strokes)
08/2017 - 08/2014
5Hemorrhage
10/2022 - 08/2014
5Venous Thrombosis (Deep-Vein Thrombosis)
10/2022 - 03/2017
4Thrombosis (Thrombus)
01/2018 - 08/2014
3Infarction (Infarctions)
04/2012 - 01/2011
2Cardiovascular Diseases (Cardiovascular Disease)
04/2012 - 09/2011
2Myocardial Ischemia (Ischemic Heart Diseases)
04/2012 - 09/2011
1Aortic Dissection
03/2017
1Pulmonary Embolism
03/2017
1Cardiogenic Shock
03/2017
1Neoplasms (Cancer)
11/2015
1Hepatitis B
09/2015
1Liver Cirrhosis (Hepatic Cirrhosis)
09/2015
1Chronic Hepatitis B
09/2015
1Heart Failure
04/2015
1Myocardial Infarction
01/2011
1Hypoxia (Hypoxemia)
08/2008
1Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
08/2008

Drug/Important Bio-Agent (IBA)

9RivaroxabanIBA
10/2022 - 08/2014
5N(4)-oleylcytosine arabinosideIBA
10/2022 - 08/2014
4spermatogenesis associated factor (SPAF)IBA
08/2017 - 04/2015
4Vitamin KFDA Link
02/2016 - 08/2014
2AnticoagulantsIBA
01/2017 - 11/2015
1Factor Xa InhibitorsIBA
10/2022
1apixabanIBA
08/2017
1Fondaparinux (Arixtra)FDA Link
03/2017
1Hepatitis B Surface Antigens (HBsAg)FDA Link
09/2015
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
09/2015
1Hepatitis C AntibodiesIBA
09/2015
1Hyaluronic Acid (Hyaluronan)IBA
09/2015
1DabigatranFDA Link
06/2015
1Prothrombin (Factor II)IBA
08/2014
1Cholinergic Agents (Cholinergics)IBA
08/2008

Therapy/Procedure

10Therapeutics
10/2022 - 04/2015
3Transplantation
04/2012 - 01/2011
2Bone Marrow Transplantation (Transplantation, Bone Marrow)
04/2012 - 09/2011
2Cell- and Tissue-Based Therapy (Cell Therapy)
09/2011 - 01/2011
1Subcutaneous Injections
03/2017
1Electric Countershock (Cardioversion)
02/2016
1Highly Active Antiretroviral Therapy (HAART)
09/2015